Takeda Pharmaceutical Company Limited (TAK)
NYSE: TAK · Real-Time Price · USD
18.28
+0.18 (0.99%)
At close: Feb 11, 2026, 4:00 PM EST
18.21
-0.07 (-0.39%)
After-hours: Feb 11, 2026, 7:32 PM EST
Takeda Pharmaceutical Employees
Takeda Pharmaceutical Company had 47,455 employees as of March 31, 2025. The number of employees decreased by 1,826 or -3.71% compared to the previous year.
Employees
47,455
Change (1Y)
-1,826
Growth (1Y)
-3.71%
Revenue / Employee
$600,047
Profits / Employee
$15,177
Market Cap
57.17B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Mar 31, 2025 | 47,455 | -1,826 | -3.71% |
| Mar 31, 2024 | 49,281 | 186 | 0.38% |
| Mar 31, 2023 | 49,095 | 1,748 | 3.69% |
| Mar 31, 2022 | 47,347 | 248 | 0.53% |
| Mar 31, 2021 | 47,099 | -396 | -0.83% |
| Mar 31, 2020 | 47,495 | -2,083 | -4.20% |
| Mar 31, 2019 | 49,578 | 22,348 | 82.07% |
| Mar 31, 2018 | 27,230 | -2,670 | -8.93% |
| Mar 31, 2017 | 29,900 | -1,268 | -4.07% |
| Mar 31, 2016 | 31,168 | -160 | -0.51% |
| Mar 31, 2015 | 31,328 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| Teva Pharmaceutical Industries | 33,950 |
| Viatris | 32,000 |
| Dr. Reddy's Laboratories | 27,811 |
| Haleon | 24,561 |
| Zoetis | 13,800 |
| Elanco Animal Health | 9,450 |
| Amneal Pharmaceuticals | 8,300 |
| Neurocrine Biosciences | 1,800 |
TAK News
- 1 day ago - U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Takeda's Oveporexton (TAK-861) as a Potential First-in-Class Therapy for Narcolepsy Type 1 - Business Wire
- 2 days ago - Takeda Taps AI Startup Iambic In $1.7 Billion+ Deal To Speed Up Drug Discovery - Benzinga
- 2 days ago - Takeda deepens AI drug discovery push with $1.7 billion Iambic deal - Reuters
- 2 days ago - Iambic Announces Collaboration with Takeda to Advance AI-Driven Design of Small Molecules - Business Wire
- 6 days ago - Japanese drugmakers slump after Trump unveils discount drug website - Reuters
- 12 days ago - Takeda Tests New Highs, But Struggles To Find Entyvio Successor - Seeking Alpha
- 13 days ago - Takeda Pharmaceutical Company Limited (TAK) Q3 2026 Earnings Call Transcript - Seeking Alpha
- 13 days ago - Takeda Reports Third-Quarter FY2025 Results: Updates Full Year Outlook to Reflect VYVANSE® Generics Impact, OPEX Discipline and FX Tailwind; Progressing Toward Three Transformative Launches Ahead - Business Wire